Breaking News

Milestone has enrolled the first patient in the Phase 3 NODE-303 study. NODE-303 is the company's open-label, global safety study of etripamil, the Company's novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia, or PSVT. The company continues to expect topline results from NODE-301 in the first half of 2020. Milestone's pivotal Phase 3 program of etripamil in PSVT, which was designed in consultation with U.S. and European Union regulatory authorities, is designed to support potential filings in the U.S. and European Union. It consists of three distinct trials. NODE-303 is a global study which will primarily evaluate the safety of etripamil when self-administered without medical supervision during single or multiple PSVT episodes.

Milestone Pharmaceuticals announced the appointment of Amit Hasija as CFO and Executive Vice President of Corporate Development. Hasija brings to Milestone two decades of experience in corporate finance and business development within the healthcare industry. Hasija most recently served as CFO and Chief Business Officer at Fulcrum Therapeutics, a publicly traded, clinical-stage biopharmaceutical company focused on developing therapies for genetically defined rare diseases. Prior to Fulcrum, he spent five years at Sanofi (SNY), most recently serving as Vice President of Integrated Care, where he was responsible for developing cardiovascular and diabetes value-based contracting models.